Introduction {#Sec1}
============

Acute kidney injury (AKI) is a serious post-operation complication in cardiac surgery patients \[[@CR1]\]; its incidence ranges from 3 to 42 % \[[@CR2]--[@CR10]\], and 1 to 5 % of AKI patients require dialysis therapy \[[@CR1], [@CR2], [@CR4], [@CR9], [@CR11]\]. The mortality of AKI patients has been reported to be as high as 40--80 % \[[@CR1], [@CR7], [@CR9]\]. Although this clinical problem is gaining increased attention, there are still no efficient methods to prevent AKI after cardiac and vascular interventions \[[@CR5], [@CR6], [@CR12]--[@CR14]\]. A double-blinded, placebo-controlled multicenter study conducted by Julier et al. \[[@CR15]\] confirmed that sevoflurane preconditioning reduces the increase in postoperative plasma cystatin C (Cys C) concentration; however, that trial did not investigate the relationship between sevoflurane preconditioning and perioperative AKI prevalence.

Remote ischemic preconditioning (RIPC) consists of cycles of transient non-fatal ischemia in one tissue to enhance the toleration of a subsequent prolonged fatal ischemia in distant organs \[[@CR16]\]. The protective mechanism of RIPC to specific organs has been illustrated by several studies \[[@CR14], [@CR17], [@CR18]\]; however, whether remote ischemic preconditioning has a positive clinical effect on renal function in cardiac and vascular surgery patients remains unclear. Some previous randomized controlled trials (RCTs) showed that RIPC reduces AKI incidence in cardiac surgery patients, but other studies had conflicting results. Several previous systematic reviews also demonstrated controversial results \[[@CR19]--[@CR23]\]. In recent years, more relevant RCTs have been carried out and published, so we performed a meta-analysis to verify the effect of RIPC on acute kidney injury in patients undergoing cardiovascular interventions.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

Studies that met the following inclusion criteria were included in this meta-analysis: (1) RCT design; (2) study participants underwent some type of elective or acute cardiac or vascular surgery; (3) RIPC intervention, regardless of the duration or number of cycles; vessel occlusion models were also included; the control group intervention was standard treatment without RIPC or with sham RIPC; and (4) report of the incidence of AKI.

The primary outcome analyzed was the incidence of AKI. The secondary outcome measures included change in renal biomarkers after surgery, the use of renal replacement therapy, in-hospital mortality, the length of hospital stay and the length of intensive care unit (ICU) stay.

Search strategy {#Sec4}
---------------

A literature search was conducted after establishing the inclusion criteria. We searched published articles in the PubMed (1966-Oct 2015), Embase (1966-Oct 2015), Google Scholar and Cochrane Library databases. We also searched ClinicalTrials.gov and Open Grey for unpublished and ongoing trials. There were no language or region restrictions. The following Medical Subject Heading terms and text words were used: ischemic preconditioning, cardiovascular surgical procedures, randomized controlled trial, controlled clinical trial, remote ischemic preconditioning. Titles and abstracts were screened by two authors (L-xC, Y-cW) to guarantee their concordance with the inclusion criteria. Full text screening was conducted by the same two persons after preliminary screening if the article's eligibility could not be determined by screening the title and abstract.

Data extraction {#Sec5}
---------------

Data extraction was performed by another two authors (Y-yL, SF) using a standardized data extraction form. Disagreements were resolved by a third person who served as an intermediary (B-jL) and made the final decision. Every trial was carefully assessed, and the following data were extracted: patient demographic characteristics, types of cardiovascular interventions, RIPC protocol, dose of contrast medium, AKI definition, incidence of AKI, in-hospital mortality, length of hospital stay, length of ICU stay, incidence of kidney replacement therapy, serum or plasma creatinine levels before and 24 and 48 h after surgery, and glomerular filtration rates (GFRs) at 24 and 48 h after surgery.

Study validity assessment {#Sec6}
-------------------------

The Jadad scale was used to evaluate the methodological quality of the eligible trials. This scoring standard examines randomization, blinding, and explanation for withdrawals and dropouts \[[@CR24], [@CR25]\]. The modified Jadad scale, which includes the additional factor of item allocation concealment, was also used, with a score of 1--3 indicating low quality and a score of 4--7 indicating high quality \[[@CR26]\]. Intention-to-treat (ITT) was also analyzed. We also judged risk of bias for each included study in terms of selection bias, performance bias, detection bias and attrition bias.

Statistical analysis {#Sec7}
--------------------

We mainly utilized the software Review Manager (RevMan) version 5.3 to analyze the extracted data (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). Risk ratios (RRs) with 95 % confidence intervals (CIs) were calculated for dichotomous outcomes, and mean differences with 95 % CI were calculated for continuous outcomes. Statistical heterogeneity was assessed using the χ^2^ test, and we determined the percentage of total variation across studies using the Higgins I^2^ statistic. We compared our primary analysis with random-effects models using the Knapp--Hartung method to determine the robustness of the pooled effects.

Results {#Sec8}
=======

Search results {#Sec9}
--------------

The search initially identified 965 articles; 234 duplicated articles and 250 animal studies were excluded. After title and abstract screening, 183 nonrandomized trials were excluded. Then, by full-text assessment of the remaining articles, we finally identified 26 eligible randomized controlled trials \[[@CR14], [@CR16], [@CR27]--[@CR50]\] (excluded articles: no target population: n = 8; no target outcomes: n = 255; no target interventions: n = 2; protocol only: n = 7, Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flowchart of article selection. *RCT* randomized controlled trial

Study characteristics {#Sec10}
---------------------

A total of 6699 patients were enrolled in the 26 included studies, with 3343 patients randomized to the RIPC group and 3356 randomized to the control group. Sixteen studies examined cardiac surgery \[[@CR14], [@CR16], [@CR28], [@CR29], [@CR31]--[@CR33], [@CR36], [@CR39], [@CR40], [@CR43], [@CR46]--[@CR50]\], six studies examined percutaneous coronary intervention \[[@CR30], [@CR34], [@CR35], [@CR37], [@CR41], [@CR45]\], and four studies examined vascular surgery \[[@CR27], [@CR38], [@CR42], [@CR44]\]. The RIPC protocols were different between studies: 24 studies used an inflatable tourniquet around the limbs \[[@CR14], [@CR16], [@CR27]--[@CR50]\], and two studies used cross-clamping of the iliac arteries \[[@CR27], [@CR44]\]. The participants in one of the studies were children \[[@CR39]\], while those of all other studies were adults. Seven studies applied contrast medium \[[@CR30], [@CR34], [@CR35], [@CR37], [@CR41], [@CR42], [@CR45]\]. The key characteristics of the included studies are shown in Table [1](#Tab1){ref-type="table"}.Table 1Demographic data of included trialsReferencesN. Patients^a^Mean age (year)^a^Males (%)^a^HTN^a^DM^a^Baseline Scr (μmol/l)^a^Surgical procedureContrast (ml)RIPC procedureAKI definitionAli et al. \[[@CR27]\]41/4174/7593/9321/262/2102/101Elective open AAA repairNoneCross-clamping of iliac arteriesPeak Scr \>177 mmol/lCandilio et al. \[[@CR28]\]89/8965/6681/7565/6728/24NACABG, valve surgeryNoneInflatable tourniquet around the limbsScr \>26.4 mmol/l or 150--200 % increase from baseline and/or urine output \<0.5 ml/kg/h for \>6 hChoi et al. \[[@CR29]\]38/3857/6038/388/101/480.4/81.3CABG, valve surgery, Bentall procedureNoneInflatable tourniquet around the limbsAKIN criterionEr et al. \[[@CR30]\]50/5073.2/72.768/7445/4632/32144.1/143.2Coronary angiography124/103Inflatable tourniquet around the limbsScr ≥25 % or ≥0.5 mg/dl increase from baselineGallagher et al. \[[@CR31]\]43/4368.7/72.876.7/83.734/3727/28121.1/121.1CABG, CABG + AVRNoneInflatable tourniquet around the limbsScr \>0.3 mg/dl increase from baseline within 48 h of surgeryHausenloy et al. \[[@CR48]\]801/82276.1/76.3556/586602/599203/211NAOn-pump CABGNoneInflatable tourniquet around the limbsKDIGO criteriaHong et al. \[[@CR32]\]35/3564.5/64.880/6623/2512/13NAOPCABNoneInflatable tourniquet around the limbsScr \>2.0 mg/dl and Scr \>0.7 mg/dl increase from baselineHong et al. \[[@CR33]\]644/64660.8/60.961.3/61.3325/297183/204NACABG, valve surgeryNoneInflatable tourniquet around the limbsScr of 2.0 mg/dl and Scr ≥0.7 mg/dl increase from baselineHoole et al. \[[@CR34]\]104/9863.2/61.881/7653/5124/20NAElective PCI196.7/187.5Inflatable tourniquet around the limbsScr \>25 % increase from baselineIgarashi et al. \[[@CR35]\]30/3071.3/70.866.7/76.7NANA101.7/99.0PCI92.9/91.8Inflatable tourniquet around the limbsL-FABP \>17.4 μg/g Cr or \>25 % increase from baseline within 24 h after use of CMKim et al. \[[@CR36]\]27/2758/5759.3/51.910/85/2NACABG, valve surgery, Bentall operationNoneInflatable tourniquet around the limbsScr \>50 % or \>0.3 mg/dl increase from baseline within 48 h after surgeryLuo et al. \[[@CR37]\]101/10459.2/59.377.2/7519/2026/31NAElective PCI154/145Inflatable tourniquet around the limbsScr \>25 % increase from baselineMeybohm et al. \[[@CR16]\]90/9070/6869/7779/7321/1772.5/77.8CABP, valve surgery, distal anastomosesNoneInflatable tourniquet around the limbsAKIN criteriaMeybohm et al. \[[@CR49]\]692/69365.8/66.0508/520573/573166/178NAElective CABGNoneInflatable tourniquet around the limbsScr ≥2 fold from baselineMurphy et al. \[[@CR38]\]31/3175/6994/7720/167/586/90Elective AAA repairNoneInflatable tourniquet around the limbsAKIN criteriaPedersen et al. \[[@CR39]\]54/511.0/0.946/65NANA35/32Operation for complex CHDNoneInflatable tourniquet around the limbsRIFLE criteriaPinaud et al. \[[@CR50]\]50/4975.8/72.927/2437/406/8NAAortic valve surgeryNoneInflatable tourniquet around the limbsAKIN criteriaRahman et al. \[[@CR40]\]80/8263/6589/8844/523/098.1/96.4CABGNoneInflatable tourniquet around the limbsScr \>0.5 mg/dl increase from baselineSavaj et al. \[[@CR41]\]48/4863.0/60.935.4/29.232/3648/48114.9/97.2Coronary angiography126.6/123.8Inflatable tourniquet around the limbsKDIGO criteriaVenugopal et al. \[[@CR43]\]38/4064/6630/3429/220/084.58/84.24Elective CABGNoneInflatable tourniquet around the limbsAKIN criteriaWalsh et al. \[[@CR42]\]18/2274/76100/1008/123/295/94Elective endovascular aneurysm repair309/286Inflatable tourniquet around the limbsDecrease in eGFR ≥20 % from baselineWalsh et al. \[[@CR44]\]22/1875/7272.7/10012/161/097/88Elective open AAA repairNoneCross-clamping of iliac arteriesDecrease in eGFR ≥20 % from baselineYamanaka et al. \[[@CR45]\]47/4767/6776/7629/3114/1772.5/76.9Emergency PCI177/199Inflatable tourniquet around the limbsScr \>0.5 mg/dl or \>25 % increase from baseline 48--72 h after use of CMYoung et al. \[[@CR46]\]48/4865.5/64.460.4/64.6NANA102/95CABG, valve surgeryNoneInflatable tourniquet around the limbsRIFLE criterionZarbock et al. \[[@CR14]\]120/12070.1/70.663.3/62.5116/11646/4497.24/106.08CABG, valve surgeryNoneInflatable tourniquet around the limbsKDIGO criteriaZimmerman et al. \[[@CR47]\]59/5962/6569/6844/5024/2182.2/84.0CABG, valve surgeryNoneInflatable tourniquet around the limbsAKIN criterion*AAA* abdominal aortic aneurysm, *AKI* acute kidney injury, *AKIN* Acute Kidney Injury Network, *HTN* hypertension, *DM* diabetes mellitus, *CABG* coronary artery bypass grafting, *CHD* congenital heart disease, *eGFR* estimated glomerular filtration rate, *NA* not available, *PCI* percutaneous coronary intervention, *RIFLE* risk, injury, failure, loss, and end-stage disease, *RIPC* remote ischemic preconditioning, *Scr* serum creatinine, *CM* contrast medium^a^RIPC group/control group

Quality assessment {#Sec11}
------------------

Two authors (YY, X-bL) independently assessed the quality of the 26 studies using the Jadad scale and the modified Jadad scale. Twenty-one (80 %) trials \[[@CR14], [@CR16], [@CR27]--[@CR29], [@CR32]--[@CR34], [@CR36]--[@CR40], [@CR42]--[@CR45], [@CR48]--[@CR50]\] had a relatively high methodological quality based on the Jadad scale, while 19 (73 %) trials \[[@CR14], [@CR16], [@CR27], [@CR28], [@CR30], [@CR32]--[@CR36], [@CR38], [@CR40], [@CR42], [@CR44], [@CR45], [@CR47]--[@CR49]\] had a relatively high methodological quality based on the modified Jadad scale. The randomization methods were adequate in 20 studies. Allocation concealment was adequate in 16 studies. Blinding was adequate in ten studies (Fig. [2](#Fig2){ref-type="fig"}). All studies had clear explanations for withdrawals and dropouts. Only six studies did not meet the ITT analysis criteria. The details of the quality assessment are shown in Table [2](#Tab2){ref-type="table"}.Table 2Quality assessment of included trialsReferencesRandomization methodAllocation concealmentBlindingExplanation for withdrawals/dropoutsIntention-to-treat analysisJadad ScoreModified Jadad ScoreAli et al. \[[@CR27]\]Computer-generated random listSealed envelopesSingle blindYesYes35Candilio et al. \[[@CR28]\]Computer-generated random listSealed envelopesDouble blindYesYes57Choi et al. \[[@CR29]\]Computerized randomization tableUnclearUnclearYesYes33Er et al. \[[@CR30]\]UnclearSealed envelopesSingle blindYesYes24Gallagher et al. \[[@CR31]\]UnclearUnclearSingle blindYesYes22Hausenloy et al. \[[@CR48]\]By means of a secure websiteSealed envelopesUnclearYesNo35Hong et al. \[[@CR32]\]Computer-generated random listSealed envelopesUnclearYesYes35Hong et al. \[[@CR33]\]Computer-generated random listSealed envelopesDouble blindYesYes57Hoole et al. \[[@CR34]\]Computer-generated randomization procedureSealed envelopesSingle blindYesNo35Igarashi et al. \[[@CR35]\]UnclearSealed envelopesNon-blindYesYes24Kim et al. \[[@CR36]\]Computer-generated random listUnclearDouble blindYesYes55Luo et al. \[[@CR37]\]Simple digital method of randomizationUnclearUnclearYesYes33Meybohm et al. \[[@CR16]\]UnclearSealed envelopesDouble blindYesNo46Meybohm et al. \[[@CR49]\]Performed by the Clinical Trial Centre LeipzigSealed envelopesDouble blindYesNo57Murphy et al. \[[@CR38]\]Computer-generated random listSealed envelopesDouble blindYesYes57Pedersen et al. \[[@CR39]\]Computerized randomization tableUnclearSingle blindYesNo33Pinaud et al. \[[@CR50]\]Computerized randomization tableUnclearSingle blindYesNo33Rahman et al. \[[@CR40]\]Computer-generated randomization procedureSealed envelopesDouble blindYesYes57Savaj et al. \[[@CR41]\]UnclearUnclearUnclearYesYes22Venugopal et al. \[[@CR43]\]Computer-generated random listUnclearSingle blindYesYes33Walsh et al. \[[@CR42]\]Computer-generated random listSealed envelopesUnclearYesYes35Walsh et al. \[[@CR44]\]Computer-generated random listSealed envelopesUnclearYesYes35Yamanaka et al. \[[@CR45]\]Computer-generated random listUnclearDouble blindYesYes55Young et al. \[[@CR46]\]Online randomization sequence generatorSealed envelopesDouble blindYesYes57Zarbock et al. \[[@CR14]\]Computer-generated random listUnclearDouble blindYesYes55Zimmerman et al. \[[@CR47]\]Block randomization generated by study coordinatorSealed envelopesSingle blindYesYes24 Fig. 2Risk of bias table: *green* low risk of bias, *yellow* unclear risk of bias, *red* high risk of bias (color figure online)

Outcomes {#Sec12}
--------

### Incidence of AKI {#Sec13}

Data regarding AKI incidence were available in all 26 studies, and the rate of AKI was significantly lower in the RIPC group than in the control group \[p = 0.01; RR 0.79 (95 % CI 0.66--0.95), Fig. [3](#Fig3){ref-type="fig"}\] (random model). However, it should be noted that different AKI definitions were applied in different studies. The AKI definitions used included the AKI Network (AKIN) criterion \[[@CR16], [@CR29], [@CR38], [@CR43], [@CR47], [@CR50]\], the Kidney Disease: Improving Global Outcomes (KDIGO) criterion \[[@CR14], [@CR41], [@CR48]\], the RIFLE criterion \[[@CR39], [@CR46]\], postoperative serum creatinine ≥0.5 mg/dl or ≥25 % above baseline \[[@CR30], [@CR34], [@CR37], [@CR40], [@CR45]\], and others \[[@CR27], [@CR28], [@CR31]--[@CR33], [@CR35], [@CR36], [@CR42], [@CR44], [@CR49]\]. We performed subgroup analyses based on the different AKI definitions. RIPC reduced AKI incidence as defined by a postoperative serum creatinine ≥0.5 mg/dl or ≥25 % above baseline \[p = 0.0002; RR 0.42 (0.27--0.67); heterogeneity χ^2^ = 3.89, I^2^ = 0 %, p for heterogeneity = 0.42\]. However, RIPC did not reduce AKI incidence in the subgroups in terms of the other AKI definitions: AKIN criterion \[p = 0.56; RR 0.87 (0.56--1.37); heterogeneity χ^2^ = 12.22, I^2^ = 59 %, p for heterogeneity = 0.03\], KDIGO criterion \[p = 0.32; RR 0.83 (0.58--1.20); heterogeneity χ^2^ = 6.76, I^2^ = 70 %, p for heterogeneity = 0.03\], RIFLE criterion \[p = 0.37; RR 0.87 (0.64--1.18); heterogeneity χ^2^ = 0.06, I^2^ = 0 %, p for heterogeneity = 0.81\], and others \[p = 0.34; RR 0.83 (0.56--1.22); heterogeneity χ^2^ = 18.85, I^2^ = 52 %, p for heterogeneity = 0.03\] (Fig. [4](#Fig4){ref-type="fig"}).Fig. 3Meta-analysis of AKI incidence between RIPC and control groups. *CI* confidence interval, *KH* Knapp--Hartung method Fig. 4Subgroup analysis for studies with different AKI definitions. *CI* confidence interval, *KH* Knapp--Hartung method

### In-hospital mortality {#Sec14}

In-hospital mortality was reported in 16 trials \[[@CR14], [@CR27], [@CR28], [@CR30], [@CR31], [@CR33], [@CR36], [@CR38]--[@CR40], [@CR42]--[@CR44], [@CR46], [@CR47], [@CR49]\], and there was no significant difference in mortality between the RIPC and control groups \[p = 0.97; RR 1.01 (0.63--1.61); heterogeneity χ^2^ = 11.84, I^2^ = 0 %, p for heterogeneity = 0.54, Fig. [5](#Fig5){ref-type="fig"}\].Fig. 5Meta-analysis of in-hospital mortality between RIPC and control groups. *CI* confidence interval, *KH* Knapp--Hartung method

### Change in renal biomarkers {#Sec15}

At 24 and 48 h after surgery, serum creatinine level was reported in five trials \[[@CR29], [@CR36], [@CR41], [@CR42], [@CR44]\] and five trials \[[@CR29], [@CR35], [@CR42], [@CR44], [@CR45]\], respectively. GFR was reported at 24 and 48 h after surgery in four trials \[[@CR29], [@CR35], [@CR42], [@CR44]\]. There were no significant differences between the two groups in serum creatinine (Scr) level or GFR at 24 or 48 h after surgery (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Meta-analysis of mean differences in kidney biomarker levels between RIPC and control groups. **a** Serum creatinine (Scr) levels at 24 h postoperatively; **b** Scr levels at 48 h postoperatively; **c** glomerular filtration rates (GFRs) at 24 h postoperatively; **d** GFRs at 48 h postoperatively. *CI* confidence interval, *KH* Knapp--Hartung method, *SD* standard deviation

### Initiation of renal replacement therapy {#Sec16}

Renal replacement therapy was reported in 15 trials \[[@CR14], [@CR27], [@CR29]--[@CR33], [@CR38]--[@CR40], [@CR42], [@CR44], [@CR47], [@CR50]\], and no significant difference was observed in the performance of renal replacement therapy between the RIPC group and the control group \[p = 0.96; RR 1.02 (0.45--2.30); heterogeneity χ^2^ = 21.35, I^2^ = 58 %, p for heterogeneity = 0.01, Fig. [7](#Fig7){ref-type="fig"}\].Fig. 7Meta-analysis of the use of renal replacement therapy between RIPC and control groups. *CI* confidence interval, *KH* Knapp--Hartung method

### The lengths of hospital stay and ICU stay {#Sec17}

Four trials reported the length of hospital stay \[[@CR29], [@CR32], [@CR36], [@CR40]\], and three trials reported the length of ICU stay \[[@CR29], [@CR32], [@CR36]\]. There was no significant difference in the length of hospital stay between the two groups \[p = 0.56; mean difference 0.37 (−0.87 to 1.61); heterogeneity χ^2^ = 5.64, I^2^ = 47 %, p for heterogeneity = 0.13\]. The length of ICU stay was remarkably reduced in the RIPC group \[p = 0.008; mean difference −0.54 (−0.95 to −0.14); heterogeneity χ^2^ = 2.08, I^2^ = 4 %, p for heterogeneity = 0.35, Fig. [8](#Fig8){ref-type="fig"}\]; however, the number of trials was too small to observe a statistically significant difference.Fig. 8Meta-analysis of **e** length of in-hospital stay and **f** length of intensive care unit (ICU) stay between RIPC and control groups. *CI* confidence interval, *KH* Knapp--Hartung method

### Subgroup analysis {#Sec18}

This meta-analysis of AKI incidence showed that RIPC reduces the perioperative incidence of AKI in cardiac and vascular surgery patients. However, there was high statistical heterogeneity among the included trials (heterogeneity χ^2^ = 46.67, I^2^ = 53 %, p for heterogeneity = 0.002, Fig. [3](#Fig3){ref-type="fig"}). Since the different AKI definitions are based on different changes in serum creatinine from baseline, and contrast applications are specific clinical settings that could influence kidney function, we performed subgroup analyses of these two potential covariates. The results of the subgroup analysis were marginally significant (Figs. [4](#Fig4){ref-type="fig"}, [9](#Fig9){ref-type="fig"}); however, meta-regression analysis indicated that different AKI definitions were not the covariate contributing significantly to heterogeneity on the risk estimate for AKI incidence \[coefficient −0.39 (−1.15 to 0.38); p = 0.56\]. We also did the meta-regression of contrast application conditions, and found that there was statistically significant difference in the risk estimate for AKI incidence \[coefficient −0.22 (−0.51 to 0.07); p = 0.039\].Fig. 9Subgroup analysis based on the use of the contrast medium intervention. *CI* confidence interval, *KH* Knapp--Hartung method

Sensitivity analysis {#Sec19}
--------------------

We used a fixed model and random model to analyze the different outcomes, and none of the results of the examined outcomes were different for these two models. These two models both indicated that remote ischemic preconditioning reduced the incidence of AKI in patients undergoing cardiovascular interventions.

Discussion {#Sec20}
==========

Many randomized controlled trials on remote ischemic preconditioning have been performed, and RIPC has been shown to ameliorate heart ischemia--reperfusion injury \[[@CR51]\]. The commonly used RIPC methods are the placement of an inflatable tourniquet around the limbs and the cross-clamping of the iliac arteries, both of which are noninvasive and nonpharmacological procedures. Cardiac and vascular surgery patients have a high risk of AKI \[[@CR1]\], and AKI increases mortality \[[@CR2]\]. However, currently, there are no effective clinical strategies for preventing the occurrence of AKI \[[@CR5], [@CR6], [@CR12]--[@CR14]\]. Remote ischemic preconditioning is a hot research area, and many researchers have applied this method to prevent AKI in cardiovascular surgery patients in recent years. However, disappointingly, the results of those studies do not clearly show whether RIPC reduces AKI incidence in cardiac and vascular surgery patients. Meta-analyses performed by other teams also failed to reach a consistent conclusion. Yasin et al. \[[@CR21]\] and Yang et al. \[[@CR22]\] performed meta-analyses, and they both found no statistically significant differences in AKI incidence between cardiovascular surgery patients who did and did not undergo RIPC. However, a meta-analysis of 13 trials conducted by Yang et al. (1134 participants) showed that RIPC decreased the risk of AKI in cardiac and vascular surgery patients \[[@CR23]\]. In addition, meta-analyses of other indices of renal impairment have not reached consistent conclusions \[[@CR19], [@CR21], [@CR22], [@CR52]--[@CR54]\]. These inconsistent results may be due to the limitation of small sample size; therefore, larger samples and meta-analyses are needed.

This meta-analysis included 6699 participants in 26 trials who underwent cardiac or vascular interventions and were randomized to a RIPC group or control group. The results of our analysis reveal that RIPC significantly reduced AKI incidence in patients undergoing cardiac or vascular interventions \[p = 0.01; RR 0.79 (0.66--0.95)\]. Because there was high statistical heterogeneity among the included trials, conclusions based on these results should be made with caution. The meta-analysis by Yang et al. indicated that the contrast medium intervention was not a covariate that significantly contributed to the heterogeneity in the risk estimate for AKI incidence, but the subgroup analysis of the contrast medium intervention in our study showed marginal statistical significance (Fig. [9](#Fig9){ref-type="fig"}). So we performed a meta-regression analysis, and the result showed that the contrast medium intervention was a covariate that significantly contributed to heterogeneity in the risk estimate for AKI incidence.

Although AKI incidence was reduced in the RIPC group, there were no significant differences in mortality or renal biomarkers between the two groups. Considering that not all of the included trials reported mortality or renal biomarkers, it is difficult to confirm whether RIPC has a kidney protective effect in patients undergoing cardiovascular interventions. Furthermore, other more sensitive indicators of early kidney damage, such as neutrophil gelatinase-associated lipocalin (NGAL) \[[@CR55]\], Cys C \[[@CR56]\] and urine output, were not available. Likewise, the use of renal replacement therapy and the length of hospital stay were not significantly different between the two groups. Length of ICU stay was shorter in the RIPC group, but that finding cannot be considered conclusive because only three trials reported valid data regarding ICU stay.

One trial only included patients without diabetes mellitus (DM) \[[@CR43]\], whereas another trial only included patients with DM \[[@CR41]\], and as DM is a potential risk factor for postoperative acute kidney injury in patients undergoing cardiac and vascular surgeries \[[@CR57]\] the findings of our study may not be generalizable to non-diabetic patients.

Our meta-analysis has some limitations. First, surgery type, anesthesia and premedication varied between trials, which may have generated different risk levels of perioperative acute kidney injury incidence. Second, there was a high level of heterogeneity in the demographic data of the patients among the included trials: Also, the baseline serum creatinine level varied considerably between studies, which may indicate differences in basic renal function between studies. We should also note that the patients in the trial by Pedersen et al. \[[@CR39]\] were children, while those in the other 25 studies were adults. Third, we did not limit this meta-analysis to studies that examined one specific RIPC procedure: two of the included studies performed cross-clamping of the iliac arteries \[[@CR27], [@CR44]\] instead of using an inflatable tourniquet around the limbs. Fourth, different AKI definitions were applied by the researchers of the different studies. All of these limitations may explain the high heterogeneity between studies besides the contrast application. Finally, only ten studies \[[@CR14], [@CR16], [@CR28], [@CR33], [@CR36], [@CR38], [@CR40], [@CR45], [@CR46], [@CR49]\] were double-blind, and we think that the single-blind and non-blind studies may have influenced the results of this meta-analysis.

Conclusion {#Sec21}
==========

Remote ischemic preconditioning can reduce the postoperative occurrence of acute kidney injury in cardiac and vascular surgery patients. However, considering the high heterogeneity among the 26 trials analyzed, we cannot draw a definitive conclusion regarding the value of RIPC at this time. A larger sample using a uniform AKI definition and RIPC method is needed to reach a more definitive conclusion.
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